Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508426 | 0.89 | EPHX1 (0.52) | EPHX1TSHRHSD11B1EPHX2CNR2 | |
| SCHEMBL5157050 | 0.88 | EPHX2 (0.44) | EPHX1TSHRHSD11B1EPHX2CNR2 | |
| SCHEMBL5158943 | 0.81 | TSHR (0.57) | EPHX1TSHRHSD11B1EPHX2ALDH1A1 | |
| SCHEMBL5157962 | 0.80 | EPHX2 (0.46) | EPHX1TSHRHSD11B1EPHX2ALDH1A1 | |
| SCHEMBL6504693 | 0.79 | EPHX1 (0.53) | EPHX1TSHRHSD11B1EPHX2ALDH1A1 | |
| SCHEMBL6502476 | 0.77 | HSD11B1 (0.57) | EPHX1HSD11B1EPHX2CNR2KMT2A | |
| SCHEMBL9891989 | 0.68 | CNR2 (0.51) | EPHX1HSD11B1EPHX2ALDH1A1CNR2 | |
| SCHEMBL9892002 | 0.68 | CNR2 (0.51) | EPHX1HSD11B1EPHX2ALDH1A1CNR2 | |
| SCHEMBL6509853 | 0.68 | EPHX1 (0.43) | EPHX1ALDH1A1CNR2KMT2A | |
| SCHEMBL2638872 | 0.67 | EPHX2 (0.57) | EPHX1TSHRHSD11B1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | EPHX1 810/4885TSHR 2376/4885HSD11B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.